Company Overview and News

4
Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

2018-09-27 zacks
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has BioLife Solutions (BLFS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
BLFS

12
BLFS / BioLife Solutions, Inc. FORM 8-K (Current Report)

2018-09-07 sec.gov - 8
bioli20180906_8k.htm UNITED STATES SECURIT
BLFS

37
The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast

2018-09-04 zacks - 1
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Turtle Beach Corp. (HEAR - Free Report) , BioLife Solutions, Inc. (BLFS - Free Report) , IntriCon Corporation (IIN - Free Report) and Medifast, Inc.
IIN RBBN NWL MED HEAR AMD BLFS

7
Trump's Approval Rating Buoy Wall Street: 4 Top Gainers

2018-08-31 zacks - 1
Per the latest survey by The Wall Street Journal and NBC News on Aug 26, President Donald Trump’s approval rating remained unaffected by the recent controversies the he found himself embroiled in. This comes as no surprise, given the fact that Trump has delivered on a lot of his promises dating back to his campaign trail.
IIN SCVL MED HEAR BLFS PAYC

12
Canopy Growth (CGC) Jumps: Stock Rises 7.4%

2018-08-30 zacks - 1
Canopy Growth Corporation (CGC - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 80.8% in the past one-month time frame.
NVMI SB CGC IPI WEED SEAC BLFS SRRA SMG

14
Bull Run to Continue in Rest of 2018: 5 Terrific Growth Picks

2018-08-29 zacks - 2
The U.S. stock markets’ bullish-run entered its longest ever expansionary phase on Aug 22. In fact, the stock markets sustained their long-term winning streak despite global trade war concerns, series of geopolitical conflicts and impending fear of rising inflation. Strong economic fundamentals of the United States suggest that the recent volatility may be transitory and that markets will continue their uptrend.
VRSZQ AFI HGR VRSZ ULH VRS HNGR VRSZW URBN PBB BLFS PSEC

4
Medtronic (MDT) Surges: Stock Moves 5.7% Higher

2018-08-22 zacks
Medtronic plc (MDT - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $88.63 to $91.22 in the past one-month time frame. The move came after the company reported solid first-quarter fiscal 2019 results.
BLFS MDT

4
PetIQ (PETQ) Catches Eye: Stock Jumps 9.1%

2018-08-21 zacks
PetIQ, Inc. (PETQ - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 40.9% in the past one-month time frame.
TOL MLNX PETQ BLFS

101
Canopy Growth (CGC) in Focus: Stock Moves 9.2% Higher

2018-08-20 zacks
Canopy Growth Corporation (CGC - Free Report) was a big mover last session, as the company saw its shares rise more than 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 32.8% in the past one-month time frame.
STZ.B TWMJF WEED STZ CGC BLFS

4
BLFS / BioLife Solutions, Inc. / Casdin Capital, LLC - null (Passive Investment)

2018-08-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
BLFS

5
BLFS / BioLife Solutions, Inc. / Casdin Capital, LLC - null (Passive Investment)

2018-08-15 sec.gov - 1
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G
BLFS

4
BLFS / BioLife Solutions, Inc. FORM 8-K (Current Report)

2018-08-15 sec.gov
bioli20180815_8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION <
BLFS

4
BLFS / BioLife Solutions, Inc. / VILLIGER WALTER - SCHEDULE 13D/A (Activist Investment)

2018-08-14 sec.gov
wv20180813_sc13da.htm SCHEDULE 13D Under the Securities Exchange Act of 1934
BLFS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to BLFS / BioLife Solutions, Inc. on message board site Silicon Investor.

BLFS dilutioin BLFS dilutioin BLFS dilutioin
CUSIP: 09062W204